Skip to search boxSkip to navigationSkip to main content

Comprehensive exome analysis of immunocompetent metastatic head and neck cancer models reveals patient relevant landscapes

  • Hui Li
    ,
  • Hoi Lam Ngan
    ,
  • Yuchen Liu
    ,
  • Helen Hoi Yin Chan
    ,
  • Peony Hiu Yan Poon
    ,
  • Chun Kit Yeung
*Corresponding author for this work
  • Chinese University of Hong Kong
    ,
  • Augusta University
    ,
  • Lee’s Pharmaceutical (HK) Limited
    ,
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

<p>Immunocompetent metastatic head and neck cancer (HNC) models, although scarce, can help understanding cancer progression and therapy responses in vivo. Their comprehensive genome characterizations are essential for translational research. We first exome-sequenced the two most widely used spontaneous metastatic immunocompetent models, namely AT-84 and SCC VII, followed by comprehensive genomic analyses with three prior-sequenced models (MOC2, MOC2-10, and 4MOSC2), together with patient tumors for utility assessment. AT-84 and SCC VII bear high HNC tumor resemblance regarding mutational signatures—Trp53, Fanconi anemia, and MAPK and PI3K pathway defects. Collectively, the five models harbor genetic aberrations across 10 cancer hallmarks and 14 signaling pathways and machineries (metabolic, epigenetic, immune evasion), to extents similar in patients. Immune defects in HLA-A (H2-Q10, H2-Q4, H2-Q7, and H2-K1), Pdcd1, Tgfb1, Il2ra, Il12a, Cd40, and Tnfrsf14 are identified. Invasion/metastatic genome analyses first highlight potential druggable ERBB4 and KRAS mutations, for advanced/metastatic oral cavity cancer, as well as known metastasis players (Muc5ac, Trem3, Trp53, and Ttn) frequently captured by all models. Notable immunotherapy and precision druggable targets (Pdcd1, Erbb4, Fgfr1, H/Kras, Jak1, and Map2k2) and three druggable hubs (RTK family, MAPK, and DNA repair pathways) are frequently represented by these models. Immunocompetent metastatic HNC models are worth developing to address therapyand invasion/metastasis-related questions in host immunity contexts.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Article number

2935

Pages from-to (Number of pages)

Pages 1-19 (19 pages)

Journal (Volume, Issue Number)

Cancers (Volume 12, Issue 10)

Publication milestones

  • Published - 10/2020

Publication status

Published - 10/2020

ISSN

2072-6694

Publication IDs

  • Scopus: 85092492945

Publication metrics

Metrics

Scopus
citations
SciVal
Author count
11
SciVal
Paper percentile
50
Fractional count
2
Fractional count
0.18
Fractional count
9
Fractional count
0.82
Fractional count
2
Fractional count
1

PlumX, opens in new tab

Captures
17
Citation count
7

Funding Details

Conflicts of Interest: V.W.Y.L. received research funding from the University-Industry Collaboration Program (UIM/329; from the Innovation and Technology Fund, Hong Kong government, and Lee’s Pharmaceutical (HK) Limited) in 2018–2020), and served as a scientific consultant for Novartis Pharmaceutical (Hong Kong SAR, China) Limited (October 2015 to October 2016). B.X.L. and W.Y.L. are from Lee’s Pharmaceutical (HK) Limited, but they have no conflicts of interest in this study. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Funding: This research was funded by the University-Industry Collaboration Program (UIM/329; Innovation and Technology Fund, Hong Kong government, Hong Kong SAR, China, and Lee’s Pharmaceutical (HK) Ltd.). V.W.Y.L. also received research funding from the General Research Fund (#17114814, #17121616, #14168517), Research Impact Fund (#R4015-19F, #R4017-18); the Health and Medical Research Fund (HMRF#15160691, the Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region, China); and the Hong Kong Cancer Fund, Hong Kong SAR, China. Y.L. received funding supports (Postdoctoral Hub PH-ITF Ref.: PiH/052/18 of UIM/329) from the Innovation and Technology Fund, Hong Kong government. V.W.Y.L. and Y.L. also received research funding from the Lee Hysan Foundation Research Grant and Endowment Fund Research Grant Schemes 2018–2019 (CA11281, V.W.Y.L.) and 2019–2020 (CA11286, V.W.Y.L.), United College, the Chinese University of Hong Kong, Hong Kong SAR, China.
FundersFunding numbers
Lee’s Pharmaceutical (HK) Limited
-
Novartis Pharmaceutical
-
University-Industry Collaboration Program
UIM/329
LHF
CA11286, CA11281
CUHK
-
FHB
-
HMRF
15160691
ITF
-
General Research Fund of Shanghai Normal University
17121616, 4015-19F, 14168517, 17114814, 4017-18
HKFC
PiH/052/18
HK
-